3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroendocrine Tumors
8
Meningioma
2
Glioblastoma
2
Sarcoma, Synovial
1
Recurrence
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Medulloblastoma
1
Glioma
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Ependymoma
1
Disease Progression
1
Carcinoid Tumor
1
Advanced Lung Neuroendocrine Tumor
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Adenoma, Islet Cell
1
Interventions
durvalumab
2
ruxolitinib
1
repotrectinib
1
pembrolizumab
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Docetaxel
1
Cyclophosphamide
1
Cisplatin
1
CPI-0610
1
Biopsy
1
Bevacizumab
1
ALT-803
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
lutetium Lu 177 dotatate
×
30 days
×
Clear all
No trials found.